InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | 2026-05-20 | Schiller Eric | Chief Technology Officer | Purchase | 5,000 | $3.91 | $20K | 5,000 | View ↗ | |
| 2026-05-15 | 2026-05-20 | Tharby Linda M | Director & Chief Executive Officer | Purchase | 1,191 | $1191.00 | $1.42M | 620.6K | View ↗ | |
| 2026-05-14 | 2026-05-18 | Pazdan Christopher | Chief Operating Officer | Purchase | 5,000 | $3.88 | $19K | 305.1K | View ↗ | |
| 2026-05-14 | 2026-05-18 | Adams Thomas Edward | Chief Financial Officer | Purchase | 5,500 | $3.86 | $21K | 308.1K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| NET REVENUES | $41.1M+22.2% | $33.6M+18.0% | $28.5M+2.2% | $27.9M+18.8% | $23.5M |
| Cost of goods sold | $15.5M+26.1% | $12.3M+4.3% | $11.8M-5.7% | $12.5M+28.9% | $9.7M |
| Gross Profit | $25.6M+20.0% | $21.3M+27.7% | $16.7M+8.7% | $15.4M+11.6% | $13.8M |
| Selling, general and administrative | $23.4M+8.1% | $21.6M+6.2% | $20.4M-1.2% | $20.6M+15.4% | $17.9M |
| Research and development | $4.4M-16.6% | $5.3M-8.4% | $5.7M+15.9% | $5.0M+100.4% | $2.5M |
| Depreciation and amortization | $811K-8.8% | $888K+2.1% | $870K+48.2% | $587K+26.8% | $463K |
| Total Operating Expenses | $28.6M+2.9% | $27.8M+3.0% | $27.0M+3.2% | $26.1M+25.7% | $20.8M |
| Net Operating Loss | -$3.0M+53.9% | -$6.4M+37.2% | -$10.3M+4.7% | -$10.8M-53.4% | -$7.0M |
| Income/(loss) on foreign currency exchange | $53K+215.5% | -$46K-797.6% | -$5K+87.1% | -$40K-37.9% | -$29K |
| Other income/(expense) | $10K+161.3% | -$16K-102.9% | $561K+285.6% | $146K+1012.8% | $13K |
| Interest income, net | $293K-34.0% | $445K-20.8% | $561K+285.6% | $146K+1012.8% | $13K |
| TOTAL OTHER INCOME | $356K-6.8% | $382K-22.9% | $496K+369.6% | $106K-84.1% | $665K |
| LOSS BEFORE TAXES | -$2.6M+56.9% | -$6.1M+38.0% | -$9.8M+8.4% | -$10.7M-67.7% | -$6.4M |
| Income tax expense | -$22K-656.7% | -$3K+99.9% | -$4.0M-297.0% | $2.0M+11.8% | $1.8M |
| NET LOSS | -$2.6M+56.5% | -$6.1M+55.9% | -$13.7M-58.7% | -$8.7M-89.8% | -$4.6M |
| Basic | $46.2M+0.8% | $45.8M+0.4% | $45.6M+1.3% | $45.0M+1.4% | $44.4M |
| Diluted | $46.2M+0.8% | $45.8M+0.4% | $45.6M+1.3% | $45.0M+1.4% | $44.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
May 2026 Penny Stocks Worth Watching
KORU Medical Systems, Inc. Q1 2026 Earnings Call Summary
KORU targets $47.5M-$50M 2026 revenue while planning next-gen Freedom60 510(k) and MDR submissions